OTCMKTS:MYRX

Myrexis Stock Forecast, Price & News

$0.06
+0.01 (+19.61 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.06
Now: $0.06▼
$0.06
50-Day Range
$0.05
MA: $0.05▼
$0.06
52-Week Range
$0.01
Now: $0.06▼
$0.08
Volume100,025 shs
Average Volume45,875 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MYRX
Previous Symbol
CUSIPN/A
CIK1459450
Webwww.myrexis.com
Phone801-214-7800
Employees1
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Myrexis, Inc. (OTCMKTS:MYRX) Sees Significant Decrease in Short Interest
April 14, 2021 |  americanbankingnews.com
Going Public with a Tax Twist: Can Investors Take a Page from KKR’s Playbook?
November 22, 2019 |  finance.yahoo.com
Myrexis: Overlooked Asset Could Deliver Big Payday In Deal
January 25, 2019 |  seekingalpha.com
See More Headlines

MarketRank™

Overall MarketRank™

0.54 out of 5 stars

Medical Sector

1481st out of 2,025 stocks

Pharmaceutical Preparations Industry

630th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.06
+0.01 (+19.61 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MYRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Myrexis (OTCMKTS:MYRX) Frequently Asked Questions

What stocks does MarketBeat like better than Myrexis?

Wall Street analysts have given Myrexis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Myrexis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Myrexis?

Myrexis saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 1,200 shares, a drop of 93.4% from the March 15th total of 18,100 shares. Based on an average daily volume of 18,900 shares, the short-interest ratio is currently 0.1 days.
View Myrexis' Short Interest.

How has Myrexis' stock price been impacted by COVID-19 (Coronavirus)?

Myrexis' stock was trading at $0.0185 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MYRX shares have increased by 229.7% and is now trading at $0.0610.
View which stocks have been most impacted by COVID-19.

Who are Myrexis' key executives?

Myrexis' management team includes the following people:
  • Mr. Jonathan M. Couchman, Chairman, CEO, Pres, CFO & Principal Accounting Officer (Age 51, Pay $1)

Who are some of Myrexis' key competitors?

Some companies that are related to Myrexis include Acusphere (ACUS), Affymax (AFFY), American Oriental Bioengineering (AOBI), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), China Health Industries (CHHE), Diadexus (DDXSQ), ERBA Diagnostics (ERBA), GelStat (GSAC), Global Future City (FTCY), Greenwich LifeSciences (GLSI), Harbor Diversified (HRBR) and Imagenetix (IAGX).
View all of MYRX's competitors.

What other stocks do shareholders of Myrexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myrexis investors own include Histogenics (HSGX), Propanc Biopharma (PPCB), New Age Brands (NF), Leidos (LDOS), FSD Pharma (HUGE), Grafenia (GRA), VAALCO Energy (EGY), (CGC), Berry (BRY) and BioLineRx (BLRX).

What is Myrexis' stock symbol?

Myrexis trades on the OTCMKTS under the ticker symbol "MYRX."

How do I buy shares of Myrexis?

Shares of MYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myrexis' stock price today?

One share of MYRX stock can currently be purchased for approximately $0.06.

How many employees does Myrexis have?

Myrexis employs 1 workers across the globe.

What is Myrexis' official website?

The official website for Myrexis is www.myrexis.com.

Where are Myrexis' headquarters?

Myrexis is headquartered at C/O XSTELOS HOLDINGS INC. 630 FIFTH AVENUE SUITE 2260, NEW YORK NY, 10020.

How can I contact Myrexis?

Myrexis' mailing address is C/O XSTELOS HOLDINGS INC. 630 FIFTH AVENUE SUITE 2260, NEW YORK NY, 10020. The biopharmaceutical company can be reached via phone at 801-214-7800 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.